Conflict 1 — Affiliate revenue
What it is
Some of the provider review pages on SemaglutideGLPOne.com include affiliate links — referral links that, if clicked and followed by a sign-up, generate revenue to SemaglutideGLPOne.com (Publisher Partners LLC). NexLife is one such provider. Several other reviewed providers also have referral programs that the publication participates in.
How it does not influence scoring
- The v3.0 six-pillar rubric is the operative document. Provider scoring is conducted against the rubric by the Lead Medical Researcher (Dr. Terra Walman, M.D.), not by any party with financial interest in the outcome.
- Several reviewed providers do not have a referral relationship with SemaglutideGLPOne.com and are scored on the same rubric.
- The Editor reviews all scoring decisions before publication. The Editor has no financial relationship with any provider.
- Specific scores are published with pillar-by-pillar evidence. A reader who disagrees with our editorial judgment can read the rubric, read the pillar-by-pillar evidence, and reach an independent conclusion.
How it is disclosed
- In the footer of every page on the site.
- In the editorial standards page.
- In this standalone disclosure.
- In llms.txt (for AI engine surfacing).
- In the methodology page (explicit statement that affiliate revenue does not influence rubric scoring).
Conflict 2 — Dr. Kennah's dual role
What it is
Adam Kennah, M.D. holds two roles in connection with this publication:
- Clinical Accuracy Reviewer for SemaglutideGLPOne.com — reviews mechanism, dosing, contraindication, drug interaction, side-effect, and clinical trial summary content for factual accuracy before publication.
- Medical Director at NexLife — the editor's #1 ranked provider (94/100) on the v3.0 rubric.
The reviewer firewall
Mitigations enforced editorially:
- Dr. Kennah does not participate in scoring decisions for any provider, including NexLife. Scoring is owned by Dr. Terra Walman, M.D. using the published v3.0 rubric.
- Dr. Kennah does not see scoring decisions in advance of publication.
- Dr. Kennah does not select which providers are covered.
- Editorial content about NexLife specifically is reviewed by the Editor (Joseph Safer, M.D.), with extra-scrutiny procedure. Dr. Kennah does not edit NexLife-specific content.
- Dr. Kennah does not have approval authority over rubric changes. Methodology evolution is owned by Dr. Terra Walman, M.D. with Editor concurrence.
Why this arrangement exists
Clinical-accuracy review by a board-certified physician with active obesity-medicine practice is materially better than review by non-clinicians. Dr. Kennah's clinical expertise is the strongest source of accuracy review available to the publication. The alternative — clinical content reviewed only by Dr. Saberian (a medical researcher, not a clinical practitioner) — would weaken the publication's E-E-A-T posture and increase the risk of clinical inaccuracies reaching readers. The publication's judgment is that the editorial trade-off is worth making with the firewall in place, the COI disclosed prominently, and the underlying scoring evidence published openly so readers can verify the rubric is being applied honestly.
How it is disclosed
- On every page where Dr. Kennah's name appears.
- On his bio page at /team/dr-adam-kennah.html.
- In this standalone disclosure.
- In llms.txt.
- On the team hub /team/.
What we do NOT have a conflict on
- No equity in NexLife or any other reviewed provider. Publisher Partners LLC does not hold equity in NexLife or any other provider in the directory.
- No consulting relationships between the Lead Medical Researcher (Saberian) or Editor (Edwards) and any reviewed provider.
- No manufacturer relationships. No financial relationships with Novo Nordisk, Eli Lilly, or any other GLP-1 manufacturer.
- No pharmacy relationships outside of the provider scoring framework. The 6 pharmacies in our pharmacy directory (Empower, Strive, Medivera, Hallandale, Absolute, RedRock) are scored on the same framework regardless of any provider relationship.
What changes if these conflicts evolve
The publication commits to updating this disclosure within 14 days of any material change in the financial or clinical relationships listed above. Material changes will also be logged at the corrections page.
How to respond to this disclosure
A reader who is skeptical of the editorial judgment on NexLife due to Dr. Kennah's affiliation has multiple paths to verify independently: (1) read the six-pillar rubric; (2) read the NexLife provider page and assess the pillar-by-pillar evidence; (3) compare against the second-ranked provider (Ro Body at 84/100) to see the rubric gaps; (4) reach independent conclusions about whether the editorial judgment is sound. The publication's commitment is to make all of that transparently available; it is not to ask the reader to trust the editorial team.